Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Astellas receives exclusive rights to develop and commercialize linaclotide compound in Asia

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.

10 Nov 2009

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Due to the increasing complexities of treating digestive diseases, allowing gastroenterological (GI) trainee physicians the opportunity to develop enhanced abilities and experiences in specific disease areas or procedures will be a great benefit to patients, according to a "Report of the Multisociety Task Force on GI Training."

4 Nov 2009

Top-line results from Phase 3 linaclotide trial for chronic constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC).

3 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

The Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-years, one of the high risk groups for contracting the H1N1 (swine) flu, and recommend this population receive the H1N1 vaccine for immunity against the disease.

30 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

Researchers explore link between workplace stress and exposure on GI disorders

In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders.

27 Oct 2009

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

27 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Pharmos announces results of its Phase 2b Dextofisopam trial

Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome.

22 Oct 2009

Lexicon Pharmaceuticals completes public offering of common stock shares

Lexicon Pharmaceuticals, Inc. today announced the completion of its previously-announced public offering of shares of its common stock. The offering included an aggregate of 38,333,332 shares of Lexicon's common stock after the exercise in full by the underwriters of their over-allotment option and by Invus, L.P., Lexicon's largest stockholder, of its associated right to purchase additional shares.

15 Oct 2009

Emisphere Technologies announces commercial launch of oral Eligen B12

Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

8 Oct 2009

Napo Pharmaceuticals hosts educational panel to address global health and environment

Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights.

8 Oct 2009

Neurocrine Biosciences enters into an amendment to its facility lease agreement

Neurocrine Biosciences, Inc. announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

5 Oct 2009

Research confirms that probiotic bacteria promotes health and boosts immune system

Functional food is the food industry's fastest-growing product group, its leading products including dairy products which contain probiotics, that is, bacteria promoting health. Valio's Lactobacillus rhamnosus GG (LGG®) is the most frequently studied and used probiotic.

5 Oct 2009

Retinoic acid may provide relief for ulcerative colitis

Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases.

3 Oct 2009

Meridian Bioscience Europe to distribute the BÜHLMANN Calprotectin test in Italy

Meridian Bioscience, Inc., Cincinnati, Ohio announced today that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue® Calprotectin.

1 Oct 2009

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

When used "off-label," the antidepressant amitriptyline works just as well as placebo in treating pain-predominant gastrointestinal disorders in children, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To view this article's video abstract, go to the AGA's YouTube Channel at www.youtube.com/AmerGastroAssn.

1 Oct 2009

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Astellas receives exclusive rights to develop and commercialize linaclotide compound in Asia

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Top-line results from Phase 3 linaclotide trial for chronic constipation

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Researchers explore link between workplace stress and exposure on GI disorders

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Pharmos announces results of its Phase 2b Dextofisopam trial

Lexicon Pharmaceuticals completes public offering of common stock shares

Emisphere Technologies announces commercial launch of oral Eligen B12

Napo Pharmaceuticals hosts educational panel to address global health and environment

Neurocrine Biosciences enters into an amendment to its facility lease agreement

Research confirms that probiotic bacteria promotes health and boosts immune system

Retinoic acid may provide relief for ulcerative colitis

Meridian Bioscience Europe to distribute the BÜHLMANN Calprotectin test in Italy

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in